WEST 2001

1 Treatments

**Studied treatment**  estrogen therapy (1 mg of estradiol-17beta per day)

**Control treatment**  placebo

**Concomittant treatments**  -

**Age (years)**  -

**Age (years)**  71 y

2 Patients

**Patients**  postmenopausal women who had recently had an ischemic stroke or transient ischemic attack

**Inclusion criteria**  postmenopausal women (amenorrhea for at least 12 months or if they had undergone hysterectomy and were older than 55 years of age); older than 44 years of age; within 90 days after a qualifying ischemic stroke or transient ischemic attack

**Exclusion criteria**  index event was disabling (had a severity score greater than 5 on the scale used in the North American Symptomatic Carotid Endarterectomy Trial) or if it occurred while the woman was taking estrogen; history of breast or endometrial cancer; venous thromboembolic event while receiving estrogen-replacement therapy; neurologic or psychiatric disease that could complicate the evaluation of end points; coexisting condition that limited their life expectancy

**type of prevention**  (secondary prevention)

**diabetes (%)**  28%

**hypertension (%)**  73%

**hyperlipidemia (%)**  -

**BMI (kg/m²)**  28

**Hysterectomy (%)**  44%

**Oophorectomy (%)**  -

3 Methods

**Blinding**  double-blind

**Design**  Parallel groups
Centers 21

Geographical area USA

Sizes 337/327

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>63/337</td>
<td>56/327</td>
<td>1,09</td>
<td>[0,73; 1,62]</td>
</tr>
<tr>
<td>venous thromboembolism</td>
<td>3/337</td>
<td>4/327</td>
<td>0,73</td>
<td>[0,16; 3,28]</td>
</tr>
<tr>
<td>PE</td>
<td>2/337</td>
<td>2/327</td>
<td>0,97</td>
<td>[0,14; 6,93]</td>
</tr>
<tr>
<td>all cause death</td>
<td>48/337</td>
<td>41/327</td>
<td>1,14</td>
<td>[0,73; 1,78]</td>
</tr>
<tr>
<td>CV events</td>
<td>88/337</td>
<td>108/327</td>
<td>0,79</td>
<td>[0,57; 1,11]</td>
</tr>
<tr>
<td>Cv death</td>
<td>11/337</td>
<td>13/327</td>
<td>0,82</td>
<td>[0,36; 1,86]</td>
</tr>
<tr>
<td>Coronary events (CHD)</td>
<td>-/337</td>
<td>-/327</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>non fatal MI</td>
<td>14/337</td>
<td>12/327</td>
<td>1,13</td>
<td>[0,52; 2,49]</td>
</tr>
</tbody>
</table>

5 References